Drug intelligence / Profile preview

CTH-501 EVs

Development stage: Preclinical
Lead developer: Cartherics
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Inhalation

Overview

CTH-501 EVs is a preclinical-stage extracellular vesicle (EV) therapeutic being developed by Cartherics. The asset is engineered to target Tumor-Associated Glycoprotein 72 (TAG-72) and Tissue Factor (TF), antigens frequently overexpressed in certain cancers and inflammatory conditions. It is currently under investigation for the treatment of endometriosis and triple-negative breast cancer (TNBC). As an EV-based modality, CTH-501 EVs leverages the inherent biocompatibility and delivery potential of extracellular vesicles to localize therapeutic effects to cells expressing the dual targets.

Other names: CTH-501 EVsCTH501 EVsCTH 501 EVsCTH-501CTH501CTH 501

Targets

F3 (Tissue factor)

Beyond the preview

Go deeper on CTH-501 EVs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTH-501 EVs.

Explore the full profile